SCHEMBL1979642

SCHEMBL1979642

COc1cc(Oc2ccc(N3C(=O)N[C@H](C(C)C)C3=O)cc2)ccc1C

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.67
MAPT P10636 5/20 0.39
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
NTRK1 P04629 1/20 0.36
IGF1R P08069 1/20 0.36
FGFR1 P11362 1/20 0.36
NTRK2 Q16620 1/20 0.36
LARS1 Q9P2J5 1/20 0.36
TSHR P16473 1/20 0.35
TAS2R8 Q9NYW2 1/20 0.35
POLB P06746 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939549 1.00 LMNA (0.67) LMNAMAPTALDH1A1HSD17B10KDM4C
SCHEMBL30939520 0.86 LMNA (0.50) LMNAMAPTALDH1A1HSD17B10KDM4C
SCHEMBL1978122 0.86 LMNA (0.50) LMNAMAPTALDH1A1HSD17B10KDM4C
SCHEMBL1978190 0.84 LMNA (0.45) LMNAMAPTALDH1A1HSD17B10KDM4C
SCHEMBL30939620 0.84 LMNA (0.45) LMNAMAPTALDH1A1HSD17B10KDM4C
SCHEMBL8722214 0.82 LMNA (0.72) LMNAMAPTALDH1A1MEN1KMT2A
SCHEMBL19805316 0.77 LMNA (0.39) LMNAMAPTALDH1A1MEN1KMT2A
SCHEMBL30939545 0.74 MAPT (0.43) LMNAMAPTALDH1A1HSD17B10KDM4C
SCHEMBL1982553 0.74 MAPT (0.43) LMNAMAPTALDH1A1HSD17B10KDM4C
SCHEMBL15547384 0.72 CYP2C9 (0.61) ALDH1A1HSD17B10MEN1KMT2ANTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US claimed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US claimed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US claimed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US claimed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US claimed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US claimed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP claimed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US claimed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US claimed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US claimed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP claimed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO claimed
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2025-01-16 US disclosed
CN-118267386-A Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-07-02 CN disclosed
CN-108472288-B Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-05-28 CN disclosed
US-11944623-B2 Modulators of Kv3 channels to treat pain AUTIFONY THERAPEUTICS LIMITED (GB) 2024-04-02 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885ALDH1A1 848/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885ALDH1A1 848/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885ALDH1A1 848/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885ALDH1A1 848/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885ALDH1A1 848/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885ALDH1A1 848/4885
US-11944623-B2 Modulators of Kv3 channels to treat pain KCNN3, KCNA3, KCND3 LMNA 2943/4885MAPT 2780/4885ALDH1A1 2716/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 LMNA 2517/4885MAPT 3789/4885ALDH1A1 462/4885
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 LMNA 2943/4885MAPT 2780/4885ALDH1A1 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.